J. Maruyama

Unraveling factors responsible for pathogenic differences in Lassa virus strains

This study identifies the L protein as a key determinant of pathogenicity in Lassa virus LF2384 compared to LF2350 in guinea pigs through immunological gene profiling and reverse genetics.

Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus

This study identifies CB1 receptor antagonists as inhibitors of Lujo virus entry by suppressing viral membrane fusion and reducing infectivity in vitro.

Machupo virus with mutations in the transmembrane domain and glycosylation sites is attenuated and immunogenic in animal models of Bolivian Hemorrhagic Fever

This paper attenuates Machupo virus by mutating glycosylation sites and a transmembrane domain residue, showing attenuation in animal models and protective efficacy against wild-type virus.

Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model

This study evaluates the efficacy of STI-2020 antibody delivered post-infection via intranasal or intravenous routes in a hamster model of COVID-19, showing reduced disease severity and duration.

Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach

This study identifies and develops human SARS-CoV-2 neutralizing antibodies using a phage display library, showing their efficacy in vivo against the virus.

A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection

This paper develops a S1-Fc vaccine targeting antigen-presenting cells, showing it elicits protective anti-SARS-CoV-2 IgG and T cell responses, with high protection at low doses.

Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection

This study shows that Type I interferons significantly reduce SARS-CoV-2 viral titers in Vero cells, with IFN-β being more effective than IFN.